What did @alexusxdominique actually say?
The creator returned to tirzepatide (Zepbound) after a two-week pause following surgery. She described being nervous about restarting at what she called a "high dosage" — dose five, noting the starting dose is 2.5 mg. She demonstrated her injection technique on-camera, showed visible anxiety about potential side effects, and mentioned she had two prescriptions remaining that she planned to use. There was no explicit medical claim made beyond her personal experience of the restart.
To be clear: this video is mostly a lifestyle injection diary, not a how-to guide. She is not telling anyone else to do what she did. That context matters when evaluating the risk level of the content. Still, nearly a million people watched this, and the framing — "why not" use the remaining prescriptions — is worth examining carefully.
Does the science back up restarting at a high dose after surgery?
Partly, but the timing and dose escalation piece is where real clinical concern lives. Restarting tirzepatide after a two-week break without dose reduction is not standard practice and carries meaningful GI risk.
Tirzepatide's half-life is approximately five days (Frias et al., 2021, New England Journal of Medicine), meaning after two weeks, drug plasma levels are substantially reduced. When you restart at the same dose after a washout period like this, you are essentially re-exposing your GI system to a dose it has not adapted to. The FDA-approved titration schedule for Zepbound exists specifically to reduce nausea, vomiting, and gastric motility disruption. Clinical trial data from the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed that the most common adverse events were gastrointestinal, peaking during dose escalation periods.
There is also a specific surgical concern. The American Society of Anesthesiologists updated its guidance in 2023 to recommend pausing GLP-1 receptor agonists before elective surgery due to delayed gastric emptying risk. Restarting post-surgery without confirmed GI recovery is a gap her prescriber should have addressed.
What did she get wrong, and what did she get right?
She got the injection technique broadly right. Pinching the skin, selecting the abdomen, and describing the device unlock mechanism are all consistent with manufacturer instructions. Credit where it is due.
What is more questionable is the framing of "I have 2 prescriptions left so why not." That phrasing treats a prescription GLP-1 agonist as something you finish because you have it, rather than because it is clinically indicated. Tirzepatide is not a Z-pack. This is a drug that alters gastric motility, suppresses appetite significantly, and in the context of post-surgical recovery, could mask symptoms of complications like delayed gastric emptying or inadequate caloric intake.
She also said she was "nervous" about being sick, which suggests she had no explicit guidance from her prescriber on how to handle the restart. That is a systems failure more than a personal one. But sharing that uncertainty with a million viewers without adding "my doctor said this was okay" is a meaningful omission.
What should you actually know before restarting a GLP-1 after a medical pause?
A two-week gap from tirzepatide is long enough to lose meaningful drug tolerance. Multiple clinical pharmacologists recommend re-titration after gaps longer than seven to ten days, though formal published guidance on this specific scenario is limited and practice varies by prescriber.
- The SURMOUNT-1 trial used a 4-week dose escalation interval for a reason: GI adaptation takes time.
- Post-surgical patients face additional risks including altered gut motility, changed absorption, and potential interaction with pain medications that also slow gastric emptying.
- If you had surgery and are on a GLP-1 agonist, your prescriber should be the one clearing the restart, with explicit guidance on whether to step down your dose first.
- "Finishing" a prescription is not a clinical rationale for continuing any medication. Tirzepatide is indicated for chronic weight management, meaning ongoing clinical oversight is part of the deal.
- The anxiety she showed is actually a reasonable signal. Nervousness about a restart at high dose, post-surgery, without clear provider guidance is appropriate. The nervous system sometimes knows what the content calendar does not.
The bottom line
This video is not dangerous misinformation. It is a personal account of a real experience shared without sufficient clinical framing. The injection technique is fine. The "why not" attitude toward a prescription GLP-1 after surgery is not. If you are considering restarting tirzepatide or any GLP-1 after a break, especially after a procedure, contact your prescriber first and ask specifically whether you need to step down your dose. Do not take your cue from someone who openly admits they do not know if they will be sick.